中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 10
Oct.  2011
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2011  >  27(10): 1102-1105

Advances in the relationship between metabolic syndrome and nonalcoholic fatty liver disease

  • Published Date: 2011-10-20
    Abstract
  • The mechanism of nonalcoholic fatty liver disease (NAFLD) is related to insulin resistance and its phenotype.Insulin resistance and compensatory hyperinsulinemia play a central role in the pathogenesis of metabolic syndrome (MS) .NAFLD is one of the clinical manifestations of MS.NAFLD is associated with atherosclerotic cardiovascular disease, type 2 diabetes and the clinical components of MS.We review the relationship between MS and NAFLD in this article.

     

    • FullText(HTML)
    • References(78)
  • [1]中华医学会.非酒精性脂肪性肝病诊疗指南[J].中华肝脏杂志, 2010, 18 (3) :163-170.
    [1]中华医学会.非酒精性脂肪性肝病诊疗指南[J].中华肝脏杂志, 2010, 18 (3) :163-170.
    [2]American Colleges of Endocrinology.ACE Position Statementon the Insulin Resistance Syndrome[S].Endocrine Practice, 2003, 9 (3) :240-252.
    [2]American Colleges of Endocrinology.ACE Position Statementon the Insulin Resistance Syndrome[S].Endocrine Practice, 2003, 9 (3) :240-252.
    [3]Petta S, Muratore C, CraxìA.Non-alcoholic fatty liver dis-ease pathogenesis:The present and the future[J].Diges-tive and Liver Disease, 2009, 41 (9) :615-625.
    [3]Petta S, Muratore C, CraxìA.Non-alcoholic fatty liver dis-ease pathogenesis:The present and the future[J].Diges-tive and Liver Disease, 2009, 41 (9) :615-625.
    [4]王燕, 陆伦根.非酒精性脂肪性肝病分子机制研究进展[J].Chin J Gastroenterol, 2010, 15 (4) :246-248.
    [4]王燕, 陆伦根.非酒精性脂肪性肝病分子机制研究进展[J].Chin J Gastroenterol, 2010, 15 (4) :246-248.
    [5]陈洁, 陈东风.非酒精性脂肪性肝病发病机制的部分进展[J].重庆医学, 2009, 38 (15) :1956-1958.
    [5]陈洁, 陈东风.非酒精性脂肪性肝病发病机制的部分进展[J].重庆医学, 2009, 38 (15) :1956-1958.
    [6]Machado M, Marques-Vidal P, Cortez-Pinto H.Hepatichistology in obese patients undergoing bariatric surgery[J].J Hepatol, 2006, 45 (4) :600-606.
    [6]Machado M, Marques-Vidal P, Cortez-Pinto H.Hepatichistology in obese patients undergoing bariatric surgery[J].J Hepatol, 2006, 45 (4) :600-606.
    [7]邹大进, 吴鸿.腹型肥胖致胰岛素抵抗的机制及治疗展望[J].中国糖尿病杂志, 2006, 14 (4) :309-312.
    [7]邹大进, 吴鸿.腹型肥胖致胰岛素抵抗的机制及治疗展望[J].中国糖尿病杂志, 2006, 14 (4) :309-312.
    [8]赵维刚, 朱慧娟.胖致胰岛素抵抗和高血糖的机制、治疗及评测[J].中国医学科学院学报, 2010, 32 (1) :7-11.
    [8]赵维刚, 朱慧娟.胖致胰岛素抵抗和高血糖的机制、治疗及评测[J].中国医学科学院学报, 2010, 32 (1) :7-11.
    [9]Qatanani M, Lazar MA.Mechanisms ofobesity-associatedinsulin resistance:many choices on the menu[J].Genes&Dev, 2007, 21:1443-1455.
    [9]Qatanani M, Lazar MA.Mechanisms ofobesity-associatedinsulin resistance:many choices on the menu[J].Genes&Dev, 2007, 21:1443-1455.
    [10]Schreuder TC, Verwer BJ, van Nieuwkerk CM, et al.Nonal-coholic fatty liver disease:An overview of current insights inpathogenesis, diagnosis and treatment[J].World J Gastro-enterol, 2008, 14 (16) :2474-2486.
    [10]Schreuder TC, Verwer BJ, van Nieuwkerk CM, et al.Nonal-coholic fatty liver disease:An overview of current insights inpathogenesis, diagnosis and treatment[J].World J Gastro-enterol, 2008, 14 (16) :2474-2486.
    [11]Després JP, Lemieux I, Bergeron J, et al.Abdominal obesi-ty and the metabolic syndrome:contribution to global cardio-metabolic risk[J].Arterioscler Thromb Vasc Biol, 2008, 28 (6) :1039-1049.
    [11]Després JP, Lemieux I, Bergeron J, et al.Abdominal obesi-ty and the metabolic syndrome:contribution to global cardio-metabolic risk[J].Arterioscler Thromb Vasc Biol, 2008, 28 (6) :1039-1049.
    [12]Zivkovic AM, German JB, Sanyal AJ.Comparative review ofdiets for the metabolic syndrome:implications for nonalco-holic fatty liver disease[J].Am J Clin Nutr, 2007, 86 (2) :285-300.
    [12]Zivkovic AM, German JB, Sanyal AJ.Comparative review ofdiets for the metabolic syndrome:implications for nonalco-holic fatty liver disease[J].Am J Clin Nutr, 2007, 86 (2) :285-300.
    [13]McAuley K, Mann J.Nutritional determinants of insulin re-sistance[J].J Lipid Res, 2006, 47:1668-1676.
    [13]McAuley K, Mann J.Nutritional determinants of insulin re-sistance[J].J Lipid Res, 2006, 47:1668-1676.
    [14]Mendoza JA, Drewnowski A, Christakis DA.Dietary energydensity is associated with obesity and the metabolic syn-drome in U.S.adults[J].Diabetes Care, 2007, 30 (4) :974-979.
    [14]Mendoza JA, Drewnowski A, Christakis DA.Dietary energydensity is associated with obesity and the metabolic syn-drome in U.S.adults[J].Diabetes Care, 2007, 30 (4) :974-979.
    [15]Valtuena S, Pellegrini N, Ardigo D, et al.Dietary glycemicindex and liver steatosis[J].Am J Clin Nutr, 2006, 84 (1) :136-142.
    [15]Valtuena S, Pellegrini N, Ardigo D, et al.Dietary glycemicindex and liver steatosis[J].Am J Clin Nutr, 2006, 84 (1) :136-142.
    [16]Vilar L, Oliveira CP, Faintuch J, et al.High-fat diet:a trig-ger of non-alcoholic steatohepati-tis?Preliminary findingsin obese subjects[J].Nutrition, 2008, 24 (11-12) :1097-1102.
    [16]Vilar L, Oliveira CP, Faintuch J, et al.High-fat diet:a trig-ger of non-alcoholic steatohepati-tis?Preliminary findingsin obese subjects[J].Nutrition, 2008, 24 (11-12) :1097-1102.
    [17]Marchesini G, Brizi M, Bianchi G, et al.Nonalcoholic fattyliver diseasea feature of the metabolic syndrome[J].Diabe-tes, 2001, 50 (18) :1844-1850.
    [17]Marchesini G, Brizi M, Bianchi G, et al.Nonalcoholic fattyliver diseasea feature of the metabolic syndrome[J].Diabe-tes, 2001, 50 (18) :1844-1850.
    [18]Targher G, Bertolini L, Padovani R, et al.Prevalence of non-alcoholic fatty liver disease and its association with cardiovas-cular disease among type 2 diabetic patients[J].DiabetesCare, 2007, 30 (5) :1212-1218.
    [18]Targher G, Bertolini L, Padovani R, et al.Prevalence of non-alcoholic fatty liver disease and its association with cardiovas-cular disease among type 2 diabetic patients[J].DiabetesCare, 2007, 30 (5) :1212-1218.
    [19]Nestel P, Lyu R, Low LP, et al.Metabolic syndrome:re-cent prevalence in East and Southeast Asian populations[J].Asia Pac J Clin Nutr, 2007, 16 (2) :362-367.
    [19]Nestel P, Lyu R, Low LP, et al.Metabolic syndrome:re-cent prevalence in East and Southeast Asian populations[J].Asia Pac J Clin Nutr, 2007, 16 (2) :362-367.
    [20]Donnelly KL, Smith CI, Schwarzenberg SJ, et al.Sourcesof fatty acids stored in liver and secreted via lipoproteins inpatients with nonalcoholic fatty liver disease[J].J Clin In-vest, 2005, 115 (5) :1343-1351.
    [20]Donnelly KL, Smith CI, Schwarzenberg SJ, et al.Sourcesof fatty acids stored in liver and secreted via lipoproteins inpatients with nonalcoholic fatty liver disease[J].J Clin In-vest, 2005, 115 (5) :1343-1351.
    [21]Park SH, Kim BI, Kim SH, et al.Body fat distribution and in-sulin resistance:beyond obesity in nonalcoholic fatty liverdisease among overweight men[J].J Am Col Nutr, 2007, 26 (4) :321-326.
    [21]Park SH, Kim BI, Kim SH, et al.Body fat distribution and in-sulin resistance:beyond obesity in nonalcoholic fatty liverdisease among overweight men[J].J Am Col Nutr, 2007, 26 (4) :321-326.
    [22]Salgado AL, Carvalho L, Oliveira AC, et al.Insulin resistanceindex (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals[J].ArgGastroenterol, 2010, 47 (2) :165-169.
    [22]Salgado AL, Carvalho L, Oliveira AC, et al.Insulin resistanceindex (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals[J].ArgGastroenterol, 2010, 47 (2) :165-169.
    [23]Hwang JH, Stein DT, Barzilai N, et al.Increased intrahepatictriglyceride is associated with peripheral insulin resistance:invivo MR imaging and spectroscopy studies[J].Am J PhysiolEndocrinol Metab, 2007, 293 (6) :E1663-E1669.
    [23]Hwang JH, Stein DT, Barzilai N, et al.Increased intrahepatictriglyceride is associated with peripheral insulin resistance:invivo MR imaging and spectroscopy studies[J].Am J PhysiolEndocrinol Metab, 2007, 293 (6) :E1663-E1669.
    [24]Musso G, Gambino R, Bo S, et al.Should nonalcoholic fattyliver disease be included in the definition of metabolic syn-drome?[J].Diabetes Care, 2008, 31 (3) :562-568.
    [24]Musso G, Gambino R, Bo S, et al.Should nonalcoholic fattyliver disease be included in the definition of metabolic syn-drome?[J].Diabetes Care, 2008, 31 (3) :562-568.
    [25] Esteghamati A, Noshad S, Khalilzadeh O, et al.Insulin re-sistance is independently associated with liver aminotrans-ferases in diabetic patients without ultrasound signs of nonal-coholic fatty liver disease[J].Prev Med, 2011, 52 (2) :174-177.
    [25] Esteghamati A, Noshad S, Khalilzadeh O, et al.Insulin re-sistance is independently associated with liver aminotrans-ferases in diabetic patients without ultrasound signs of nonal-coholic fatty liver disease[J].Prev Med, 2011, 52 (2) :174-177.
    [26]Liu Q, Bengmark S, Qu S.The role of hepatic fat accumula-tion in pathogenesis of non-alcoholic fatty liver disease[J].Lipids Health Dis, 2010, 9:42.
    [26]Liu Q, Bengmark S, Qu S.The role of hepatic fat accumula-tion in pathogenesis of non-alcoholic fatty liver disease[J].Lipids Health Dis, 2010, 9:42.
    [27] Targher G, Bertolini L, Felice Poli, et al.Nonalcoholic fattyliver disease and risk of future cardiovascular events amongtype 2 diabetic patients[J].Diabetes, 2005, 54 (12) :3541-3546.
    [27] Targher G, Bertolini L, Felice Poli, et al.Nonalcoholic fattyliver disease and risk of future cardiovascular events amongtype 2 diabetic patients[J].Diabetes, 2005, 54 (12) :3541-3546.
    [28]Vozarova B, Stefan N, Lindsay RS, et al.High alanine amin-otransferase is associated with decreased hepatic insulin sen-sitivity and predicts the development of type 2 diabetes[J].Diabetes, 2002, 51 (6) :1889-1895.
    [28]Vozarova B, Stefan N, Lindsay RS, et al.High alanine amin-otransferase is associated with decreased hepatic insulin sen-sitivity and predicts the development of type 2 diabetes[J].Diabetes, 2002, 51 (6) :1889-1895.
    [29]Wanless IR, Lentz JS.Fatty liver hepatitis (steatohepatitis) and obesity:an autopsystudy with analysis of risk factors[J].Hepatology, 1990, 12 (5) :1106-1110.
    [29]Wanless IR, Lentz JS.Fatty liver hepatitis (steatohepatitis) and obesity:an autopsystudy with analysis of risk factors[J].Hepatology, 1990, 12 (5) :1106-1110.
    [30]Shibata M, Kihara Y, Taguchi M, et al.Nonalcoholic fatty liv-er disease is a risk factor for type 2 diabetes in middle-agedjapanese men[J].Diabetes Care, 2007, 30 (11) :2940-2944.
    [30]Shibata M, Kihara Y, Taguchi M, et al.Nonalcoholic fatty liv-er disease is a risk factor for type 2 diabetes in middle-agedjapanese men[J].Diabetes Care, 2007, 30 (11) :2940-2944.
    [31]Targher G, Bertolini L, Poli F, et al.Nonalcoholic fatty liverdisease and risk of future cardiovascular events among type 2diabetic patients[J].Diabetes, 2005, 54 (12) :3541-3546.
    [31]Targher G, Bertolini L, Poli F, et al.Nonalcoholic fatty liverdisease and risk of future cardiovascular events among type 2diabetic patients[J].Diabetes, 2005, 54 (12) :3541-3546.
    [32]Targher G, Bertolini L, Rodella S, et al.Nonalcoholic fattyliver disease is independently associated with an increasedincidence of cardiovascular events in type 2 diabetic patients[J].Diabetes Care, 2007, 30 (8) :2119-212.
    [32]Targher G, Bertolini L, Rodella S, et al.Nonalcoholic fattyliver disease is independently associated with an increasedincidence of cardiovascular events in type 2 diabetic patients[J].Diabetes Care, 2007, 30 (8) :2119-212.
    [33]Brea A, Mosquera D, Martín E, et al.Nonalcoholic fatty liverdisease is associated with carotid atherosclerosis:a case-control study[J].Arterioscler Thromb Vasc Biol, 2005, 25 (5) :1045-1050.
    [33]Brea A, Mosquera D, Martín E, et al.Nonalcoholic fatty liverdisease is associated with carotid atherosclerosis:a case-control study[J].Arterioscler Thromb Vasc Biol, 2005, 25 (5) :1045-1050.
    [34]Assy N, Djibre A, Farah R, et al.Presence of coronaryplaques in patients with nonalcoholic fatty liver disease[J].Radiology, 2010, 254 (2) :393-400.
    [34]Assy N, Djibre A, Farah R, et al.Presence of coronaryplaques in patients with nonalcoholic fatty liver disease[J].Radiology, 2010, 254 (2) :393-400.
    [35]Choi SY, Kim D, Kim HJ, et al.The relation between non-alcoholic fatty liver disease and the risk of coronary heart dis-ease in Koreans[J].Am J Gastroenterol, 2009, 104 (8) :1953-1960.
    [35]Choi SY, Kim D, Kim HJ, et al.The relation between non-alcoholic fatty liver disease and the risk of coronary heart dis-ease in Koreans[J].Am J Gastroenterol, 2009, 104 (8) :1953-1960.
    [36]Roberts EA.Pediatric Nonalcoholic fatty liver disease (NAFLD) :A“growing”problem[J].J hepatol, 2007, 46 (6) :1133-1142.
    [36]Roberts EA.Pediatric Nonalcoholic fatty liver disease (NAFLD) :A“growing”problem[J].J hepatol, 2007, 46 (6) :1133-1142.
    [37]Valerio Nobili, Matilde Marcellini, Rita Devito, et al.NAFLDin children:a prospective Cli nical-pathological study andeffect of lifestyle advice[J].Hepatology, 2006, 44 (2) :458-465.
    [37]Valerio Nobili, Matilde Marcellini, Rita Devito, et al.NAFLDin children:a prospective Cli nical-pathological study andeffect of lifestyle advice[J].Hepatology, 2006, 44 (2) :458-465.
    [38]Patton HM, Yates K, Unalp-Arida A, et al.Association be-tween metabolic syndrome and liver histology among childrenwith nonalcoholic fatty liver disease[J].Am J Gastroenterol, 2010, 105 (9) :2093-2102.
    [38]Patton HM, Yates K, Unalp-Arida A, et al.Association be-tween metabolic syndrome and liver histology among childrenwith nonalcoholic fatty liver disease[J].Am J Gastroenterol, 2010, 105 (9) :2093-2102.
    [39]Ratziu V, Bellentani S, Cortez-Pinto H, et al.A positionstatement on NAFLD/NASH based on the EASL 2009 specialconference[J].J Hepatol, 2010, 53 (2) :372-384.
    [39]Ratziu V, Bellentani S, Cortez-Pinto H, et al.A positionstatement on NAFLD/NASH based on the EASL 2009 specialconference[J].J Hepatol, 2010, 53 (2) :372-384.
    • Relative Articles

  • Relative Articles

    [1]Yuxin WANG, Weigang GU, Zheng JIN, Xiaofeng ZHANG. Successful treatment of biliary fistula after Beger surgery by oral choledochoscopy-assisted percutaneous-endoscopic rendezvous technique： A case report[J]. Journal of Clinical Hepatology, 2025, 41(2): 333-336. doi: 10.12449/JCH250220
    [2]Wenqian GENG, Chong WANG, Hang LI, Junqi NIU, Fang XU. Clinical features of portal biliopathy[J]. Journal of Clinical Hepatology, 2023, 39(11): 2651-2656. doi: 10.3969/j.issn.1001-5256.2023.11.020
    [3]Peng JIANG, Shupeng WANG, Yahui LIU. A case of portal biliopathy[J]. Journal of Clinical Hepatology, 2022, 38(2): 430-432. doi: 10.3969/j.issn.1001-5256.2022.02.034
    [4]Peng FengHui, Liu Kai, Yang Yang, Liu YaHui, Ji Bo. Biliary stent implantation for malignant obstructive jaundice through the percutaneous transhepatic biliary drainage pathway: A report of 2 cases[J]. Journal of Clinical Hepatology, 2019, 35(7): 1601-1603. doi: 10.3969/j.issn.1001-5256.2019.07.038
    [5]The Society of Interventional Therapy, China Anti-Cancer Association. Expert consensus of percutaneous transhepatic biliary drainage and stent implantation in treatment of obstructive jaundice(2018 Edition)[J]. Journal of Clinical Hepatology, 2019, 35(3): 504-508. doi: 10.3969/j.issn.1001-5256.2019.03.010
    [6]Xu Gang. Clinical effect of biliary metal stent implantation via endoscopic retrograde cholangiopancreatography in treatment of unresectable malignant extrahepatic biliary obstruction[J]. Journal of Clinical Hepatology, 2018, 34(2): 337-340. doi: 10.3969/j.issn.1001-5256.2018.02.023
    [7]Wang DaHai, Dai YongZe. Clinical effect of integrated traditional Chinese and Western medicine therapy in treatment of biliary ascariasis[J]. Journal of Clinical Hepatology, 2017, 33(2): 313-315. doi: 10.3969/j.issn.1001-5256.2017.02.023
    [8]Tian Xing, Chen YanZhen, Chen ChengLiang, Jiao Jian. Advances in pathogenesis and minimally invasive therapies for extrahepatic portal biliopathy[J]. Journal of Clinical Hepatology, 2017, 33(6): 1192-1195. doi: 10.3969/j.issn.1001-5256.2017.06.038
    [9]Xing TongChao, Ren Bin, Wang YuPeng, Yang DongXing. Clinical effect of choledochofiberscope-assisted secondary surgery in treatment of intrahepatic and extrahepatic biliary stones[J]. Journal of Clinical Hepatology, 2015, 31(8): 1325-1327. doi: 10.3969/j.issn.1001-5256.2015.08.036
    [10]Zhang Kai, Zhang MengFan, Ren JianZhuang, Huang GuoHao, Wang YanLi, Duan XuHua, Chen PengFei, Han XinWei. Efficacy of percutaneous intraductal radiofrequency ablation combined with biliary stenting in treatment of malignant biliary obstruction[J]. Journal of Clinical Hepatology, 2015, 31(5): 737-740. doi: 10.3969/j.issn.1001-5256.2015.05.025
    [11]Chen Peng, Hu LiHua, Cai Yu, Shi ChunLin, Zhang PeiYi. Outcome of five cases of balloon dilatation to remove common bile duct residual stones via the T-tube tract[J]. Journal of Clinical Hepatology, 2013, 29(3): 230-231.
    [12]Zhang RuLing, Lu LunGen. Current situation and future prospect of cholangiopathy[J]. Journal of Clinical Hepatology, 2012, 28(7): 481-483.
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3712) PDF downloads(1086) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2329]YesterdayPV[4431]TodayIP[307]TodayPV[460]Online[25]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return